A Phase I study investigated treatment with dabrafenib and lapatinib, the latter being a dual HER2/neu and epidermal-growth factor-receptor (EGFR) inhibitor, in patients with unresectable-radioiodine refractory thyroid cancer (ClinicalTrials.gov Identifier: NCT01947023). Here, ERBB2 is linked to thyroid cancer.